The global C-reactive protein (CRP) market continues to represent a vital segment of the in-vitro diagnostics (IVD) industry. As a key biomarker for inflammation, CRP testing has become indispensable for diagnosing and managing conditions ranging from cardiovascular diseases to autoimmune disorders.

Market Overview

C-reactive protein is a substance produced by the liver in response to inflammation. The market is primarily driven by the rising prevalence of chronic inflammatory diseases and the increasing integration of high-sensitivity CRP (hs-CRP) tests into routine cardiovascular risk assessments.

According to data analyzed by Data Bridge Market Research, the market was valued at USD 5.53 billion in 2021 and is projected to reach USD 6.06 billion by 2029, progressing at a CAGR of 1.15%. For the immediate 2025 forecast year, the market is estimated to reach approximately USD 5.79 billion, reflecting steady adoption in both clinical and point-of-care (POC) settings.

Market Share and Size (2025 Data)

The market's expansion is fueled by the transition from traditional laboratory-based testing to rapid, decentralized diagnostics.

2021 Value: USD 5.53 Billion

2025 Forecast Value: ~USD 5.79 Billion

2029 Projected Value: USD 6.06 Billion

CAGR: 1.15% (2022–2029)

North America currently holds the largest market share, attributed to advanced healthcare infrastructure and high healthcare spending. However, the Asia-Pacific region is expected to witness the highest growth rate due to an aging population and increasing awareness of preventive health screenings.

Get a Sample Report of C-reactive protein Forecast @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-c-reactive-protein-market

Market Segmentation

The C-reactive protein market is categorized based on technology, application, and end-user to provide a comprehensive view of industry dynamics.

1. By Assay Type

Immunoturbidimetric Assay: The dominant segment due to its cost-effectiveness and compatibility with automated laboratory analyzers.

ELISA (Enzyme-Linked Immunosorbent Assay): Preferred for high-sensitivity requirements.

Chemiluminescence Immunoassay (CLIA): Gaining traction for its superior sensitivity and range.

2. By Detection Range

hs-CRP (High-sensitivity CRP): Used primarily for assessing cardiovascular risk.

Conventional CRP: Standard for detecting acute infection and general inflammation.

3. By Disease Application

Cardiovascular Disease (CVD)

Rheumatoid Arthritis & Autoimmune Diseases

Infectious Diseases

Cancer & Inflammatory Bowel Disease (IBD)

4. By End-User

Hospitals and Clinics

Diagnostic Laboratories

Point-of-Care Testing (POCT) Facilities

Do you have any specific queries or need any C-reactive protein Submit your inquiry here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-c-reactive-protein-market

Key Market Players in C-reactive protein

The competitive landscape is characterized by established diagnostic giants and innovative emerging firms focusing on portable testing solutions. Key players include:

Thermo Fisher Scientific, Inc. (U.S.)

F. Hoffmann-La Roche Ltd. (Switzerland)

Danaher (U.S.)

Quest Diagnostics Incorporated (U.S.)

Siemens Healthcare GmbH (Germany)

Abbott (U.S.)

Merck KGaA (Germany)

Zoetis (U.S.) – Leading the veterinary CRP segment.

Ortho Clinical Diagnostics (U.S.)

Getein Biotech, Inc. (China)

HORIBA, Ltd (Japan)

Randox Laboratories Ltd. (U.K.)

Boditech Med, Inc. (South Korea)

Aidian (Finland)

SD Biosensor, INC. (South Korea)

Teco Diagnostics (U.S.)

Arlington Scientific, Inc. (U.S.)

Get A Buy Now Report C-reactive protein Forecast @https://www.databridgemarketresearch.com/checkout/buy/global-c-reactive-protein-market/compare-licence

Inflammation Biomarker Analysis

Modern diagnostic strategies are increasingly relying on inflammation biomarker analysis to differentiate between viral and bacterial infections. This approach reduces the unnecessary prescription of antibiotics, aligning with global antimicrobial stewardship goals. The integration of CRP testing into multiplex panels—where it is measured alongside other markers like Procalcitonin—is a significant trend expected to bolster market value through 2026.

Future Outlook

The C-reactive protein market is positioned for stable growth as healthcare systems shift toward preventive and personalized medicine. With a projected value of over USD 6 billion by 2029, the market benefits from technological advancements in point-of-care diagnostics and a heightened focus on managing chronic inflammatory conditions. While established players like Roche and Abbott lead in market share, the expansion of healthcare access in emerging economies provides a fertile ground for localized diagnostic providers.

About Us:
Data Bridge is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact :
Data Bridge Market Research Private Ltd .
3665 Kingsway - Suite 300 Vancouver BC V5R 5W2 Canada
+1 614 591 3140 (US)
+44 845 154 9652 (UK)
Email: Sales@databridgemarketresearch.com
Website: https://www.databridgemarketresearch.com